Abstract
Objective:
The authors investigated the role of acute serotonergic modulation in the efficacy of selective serotonin reuptake inhibitors (SSRIs) in women with premenstrual dysphoric disorder.
Method:
Patients with premenstrual dysphoric disorder (whose symptoms had remitted during treatment with fluoxetine) and a group of unmedicated healthy comparison women received the serotonin receptor antagonist metergoline as part of a double-blind, placebo-controlled crossover study.
Results:
The patients with premenstrual dysphoric disorder experienced a return of symptoms 24 hours after treatment with metergoline but not diphenhydramine (active placebo). The comparison women experienced no changes in mood.
Conclusions:
These data support the role of altered serotonergic transmission in the efficacy of SSRI treatment for premenstrual dysphoric disorder.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Affect / drug effects
-
Affect / physiology
-
Depression / diagnosis
-
Depression / drug therapy
-
Depression / physiopathology*
-
Depression / psychology
-
Diphenhydramine / adverse effects
-
Diphenhydramine / therapeutic use
-
Double-Blind Method
-
Female
-
Fluoxetine / adverse effects
-
Fluoxetine / therapeutic use
-
Humans
-
Metergoline*
-
Personality Inventory
-
Premenstrual Syndrome / diagnosis
-
Premenstrual Syndrome / drug therapy
-
Premenstrual Syndrome / physiopathology*
-
Premenstrual Syndrome / psychology
-
Receptors, Serotonin / drug effects
-
Receptors, Serotonin / physiology*
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Serotonin Antagonists*
-
Treatment Outcome
Substances
-
Receptors, Serotonin
-
Serotonin Antagonists
-
Serotonin Uptake Inhibitors
-
Fluoxetine
-
Metergoline
-
Diphenhydramine